|10:00 (5 min.)||Welcome and Introductions||Timothy L. EnnsSVP, Corporate Communications and Marketing|
|10:05 (15 min.)||Corporate Overview||James S. J. Manuso, Ph.D.Chairman and Chief Executive Officer|
|10:20 (15 min.)||Financial Overview||Michael Molkentin, C.P.A.Chief Financial Officer and Corporate Secretary|
|10:35 (15 min.) 10:50 (20 min.)||Clinical UpdateSGI-110 & HMAs||Mohammad Azab, M.D.Chief Medical Officer Jean-Pierre Issa, MDFels Institute of Cancer ResearchTemple University, Philadelphia, PA|
|11:10 (20 min.)||AT 13387 & HSP90 inhibitors||Andrew Wagner, MD, PhDDana Farber Cancer Institute, Boston, MA|
|11:30 (15 min.) 11:45 (15 min.)||Research & DiscoveryPartnering & Corporate Development||Harren Jhoti, Ph.D.President and Director Martin BucklandChief Business Officer|
|12:00 (5 min.)||Closing Remarks||James S. J. Manuso, Ph.D.Chairman and Chief Executive Officer|
About Astex PharmaceuticalsAstex Pharmaceuticals is dedicated to the discovery and development of novel small molecule therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales. For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.